CD99 and neoplasm: Immunohistochemical analysis of CD99, HRNR, and CANX confirmed the expression of these markers in the prostate but, due to high heterogeneity, with high- and low-expression areas in both healthy and tumor tissues, it was not possible to compare the two conditions (Figure S2).